After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Earlier, Yahoo Finance discussed this stock as it revealed Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $3.59 and fluctuated between $3.6759 as its day high and $3.5300 as its day low. The current market capitalization of Aldeyra Therapeutics Inc is $211.16M. A total of 0.5 million shares were traded on the day, compared to an average of 1.06M shares.
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, ALDX has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 7 BUYs and 3 SELLs from insiders. Insiders purchased 536,453 shares during that period but sold 2,830,306.
In the most recent transaction, PERCEPTIVE ADVISORS LLC sold 306,499 shares of ALDX for 1.74 per share on Oct 18. After the transaction, the 10% Owner now owns 8,593,586 company shares. In a previous transaction on Oct 16, PERCEPTIVE ADVISORS LLC sold 2,450,000 shares at 1.60 per share. ALDX shares that 10% Owner owns now total 8,900,085.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for ALDX in the last 3 months, the mean price target is $9.00 with high estimates of $11.00 and low estimates of $7.00. In terms of 52-week highs and lows, ALDX has a high of $11.97 and a low of $1.42.
As of this writing, ALDX has an earnings estimate of $Ardelyx, Inc. per share for the current quarter. EPS was calculated based on a consensus of USCF Gold Strategy Plus Income estimates, with a high estimate of $Celldex Therapeutics, Inc. per share and a lower estimate of $Aldeyra Therapeutics, Inc.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. ALDX’s latest balance sheet shows that the firm has $229.79M in Cash & Short Term Investments as of fiscal 2021. There were $15.86M in debt and $11.77M in liabilities at the time. Its Book Value Per Share was $2.08, while its Total Shareholder’s Equity was $205.74M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ALDX is Buy with a score of 4.60.
